DKSH, a Market Expansion Services provider with a focus on Asia, has established a partnership with Minsheng Pharma to market and distribute the company’s Baini eye drops (Bendazac Lysine) in China. DKSH will provide marketing and sales, distribution and logistics and after-sales services for the product to pharmacies and hospitals in China. Bainiis one of Minsheng Pharma’s flagship products aimed at preventing cataracts.

“We are seeing great potential in the medicine market for elderly. The growth rate of cataract prevention medicine has been continuously high in the past few years. It is important for us to work with the leading Market Expansion Services provider to market and distribute Baini that has tremendous potential for business success. Through DKSH’s healthcare capabilities in China, we will be able to make Baini available to more patients across the country, and we will have a stronger presence and market share in the over-the-counter market,” said Yang Jun, general manager, Hangzhou Minsheng Pharmaceutical Co., Ltd. “We are further expanding our ophthalmology product line through R&D and acquisitions and expect to add more products to our cooperation with DKSH in the near future.”

“The new partnership with Minsheng Pharma is testament to our capabilities and strength in the over-the-counter and medical channel, which are key pillars in our business model. We are proud to be working with Minsheng Pharma to provide our commercial services for initially their ophthalmology product. Minsheng is a very prominent company and is active in many therapeutic areas. We expect to expand our cooperation step by step,” said John Woo, head of Country Management Team for DKSH China.